Altered gut microbiota correlate with different immune response to HAART in HIV-infected individuals

Yirui Xie (✉ 1312019@zju.edu.cn)
Zhejiang University School of Medicine First Affiliated Hospital

Jia Sun
Zhejiang University School of Medicine First Affiliated Hospital

Li Wei
Zhejiang University School of Medicine First Affiliated Hospital

Haiyin Jiang
Zhejiang University School of Medicine First Affiliated Hospital

Caiqin Hu
Zhejiang University School of Medicine First Affiliated Hospital

Jiezuan Yang
Zhejiang University School of Medicine First Affiliated Hospital

Ying Huang
Zhejiang University School of Medicine First Affiliated Hospital

Bing Ruan
Zhejiang University School of Medicine First Affiliated Hospital

Biao Zhu
Zhejiang University School of Medicine First Affiliated Hospital

Research article

Keywords: HIV-1, Gut microbiota, immune activation, immunological responders, immunological non-responders, HAART

DOI: https://doi.org/10.21203/rs.3.rs-44062/v3

License: ☑️ ⓘ This work is licensed under a Creative Commons Attribution 4.0 International License.

Read Full License
Abstract

**Background:** Although gut microbiota dysbiosis has been reported in HIV infected individuals recently, the relationship between the gut microbiota and immune activation in patients with different immune responses to highly active antiretroviral therapy (HAART) is still not well understood. Gut microbiota and immune activation were studied in 36 non-HIV-infected subjects (healthy controls) and 58 HIV-infected individuals, including 28 immunological responders (IR) and 30 immunological non-responders (INR) (≥500 and <200 CD4+ T-cell counts/µl after 2 years of HIV-1 viral suppression respectively) without comorbidities.

**Results:** Metagenome sequencing revealed that HIV-infected immunological responders and immunological non-responders could not recover completely from the gut microbiota dysbiosis. At a 97% similarity level, the relative abundances of Fusobacterium, Ruminococcus gnavus and Megamonas were greater, whereas Faecalibacterium, Alistipes, Bifidobacterium, Eubacterium rectale and Roseburia were more depleted in the IR and INR groups than those in the healthy controls. Ruminococcaceae and Alistipes were positively correlated with nadir and current CD4+ T-cell counts, but negatively correlated with CD8+CD57+ T-cell counts. Inflammation markers and translocation biomarkers (LPS) levels were positively correlated with the abundances of genus Ruminococcus and Fusobacterium but were negatively correlated with the genus Faecalibacterium. The relative abundances of Escherichia-Shigella and Blautia were significantly higher in the IR than those in the INR group. Escherichia-Shigella were negatively correlated with the CD4/CD8 ratio but positively correlated with the amount of CD8+CD57+ T-cells. Roseburia and Blautia were negatively associated with nadir CD4+ T-cell and positively associated with CD8+CD57+ T-cell counts.

**Conclusions:** Gut microbiota dysbiosis may be one of the factors contributing to different immune responses and treatment outcomes to HAART.

**Background**

Life expectancy of individuals infected with human immunodeficiency virus (HIV) has increased enormously and HIV infection has become a chronic disease that is manageable in the combination antiretroviral therapy (ART) era. Most patients receiving ART can achieve a distinct reduction of HIV viral load and improvement of CD4+ T-cell counts compared with nadir CD4+ T-cell counts (the patient's lowest CD4+ T-cell counts). However, the extent of immunological recovery varies greatly between individuals. The HIV-infected individuals who fail to achieve normalization of CD4+ T-cell counts despite persistent virological suppression are considered as immunological non-responders (INR)[1], which are in contrast with immunological responders (IR) [2]. As there is no unified definition of INR, the prevalence of INR ranges from 15% to 30% in the ART cohorts [3-5]. The INR were defined as patients whose absolute value of CD4+ T cells counts were less than 200 cells/µl after years of ART, although 350 cells/µl were also used as a cutoff value in the literature [6]. In contrast, IR were defined as patients whose CD4+ T-cell counts were greater than 500 cells/µl after receiving ART for years.
Emerging evidence suggests that the gut microbiome of HIV-infected patients are different from that of HIV-uninfected individuals [7]. However, these studies have not taken considered the immune response to ART and there have been few researches focusing on patients in China [7]. Recently, several studies have reported that gut microbiota is associated with CD4+ T-cell recovery in HIV-infected patients [8-10]. The microbiome of chronic HIV infected individuals was studied in China. However, these patients had heterogeneous HIV progression and immune response to ART [11, 12]. Studies showed that HIV-mediated destruction of gut mucosa could lead to local and systemic inflammation [13]. Moreover, chronic inflammation was reported to be associated with the gut microbiome in the non-AIDS population [14]. These studies suggest that the gut microbiome may play a part in the immune activation in HIV-infected individuals with ART [13, 15-17]. Despite many studies of the microbiome in HIV-infected patients, there have been relatively few reports discussing the gut microbiome that occur in patients with different immune responses to ART [18, 19]. Therefore, a comparative study of the gut microbiome and immune activation was conducted on HIV patients with different immune responses to ART and the results are presented in this study. 16S ribosomal RNA (rRNA) targeted sequencing and flow cytometry were used to characterize the gut microbiome and their relationship with immune activation among immunodiscordant and immunoconcordant patients with long-term suppressive ART.

Results

Clinical characteristics and pyrosequencing data summary

The characteristics of all 28 IR patients, 30 INR patients and 36 healthy controls, including demographics, clinical characteristics, and pyrosequencing results are presented in Table 1. There is no significant difference between the rate of the transmission route in the IR and INR groups (p=0.779). The rate of homosexual (MSM) transmission route is 57.1% vs 51.7% in the INR and IR groups, whereas the rate of the heterosexual transmission route is 20.7% vs 21.4%, and other rates are missing from their records. The viral load of all HIV-infected individuals with ART is not detected. Nadir and current CD4+ T cell counts are significantly higher in the IR group than the INR group (Table 2). No differences in the duration of ART and ongoing ART medications are observed between the IR and the INR groups. Other characteristics such as gender, age and body mass index (BMI) are generally matched among the IR, INR and healthy controls. 3,549,077 high-quality sequences in total were obtained (average sequence length 440 bp) from 94 participants. 38,849 sequences per sample on average were obtained from the healthy controls, while 35,947 and 38,134 sequences per sample were obtained respectively from the IR and INR patients. Rarefaction was conducted on the OTU (Operational taxonomic unit) table to 30,174 reads per sample to avoid methodological artefacts. Specifically, 609 OTUs are defined in the healthy controls, while 486 OTUs and 567 OTUs in the IR and INR groups are defined relatively at a 97% similarity level. Significant differences of bacterial diversity (Shannon, Simpson, and Sobs), richness (ACE, Chao1) and Good’s coverage are observed among the three groups, while no significant difference are found between the IR and the INR groups. A summary is shown in Table 2.

Compositional analysis of fecal microbiota
Principal coordinate analysis (PCoA) by weighted UniFrac matrices shows obvious differentiation of bacterial communities between the IR and the healthy controls (PERMANOVA, pseudo-F: 8.99, $R^2=0.13$, $P =0.001$, Fig.1a), the INR and the healthy controls (PERMANOVA, pseudo-F: 8.77, $R^2=0.12$, $P =0.001$, Fig.1b), while no significant differences are observed between the IR and INR groups (PERMANOVA, pseudo-F: 0.80, $R^2=0.01$, $P =0.71$, Fig. 1c).

The data of average relative abundance of each bacterial phylum and genus in patients and the healthy controls are showed respectively in the figures (Fig. 2; S1, S2 and S3 Fig) and table (S1 Table). The Wilcoxon rank sum test was used to detect taxa with significant differences in relative abundances among groups (confidence interval method). At the phylum level, Bacteroidetes, Actinobacteria, Tenericutes and Lentisphaerae are more abundant in the healthy controls than in the IR group. The relative abundances of Proteobacteria, Fusobacteria and Saccharibacteria are significantly higher in the IR group (S1 Fig. 2a) than those in the healthy controls. The relative abundances of 11 families are significantly different between the IR and the healthy controls. The relative abundances of 93 genera, including 15 predominant (>1% of the total sequences in either group) and 78 less-predominant genera, are significantly different between the healthy controls and the IR groups. Among the different predominant genera, *Lachnoclostridium*, *Megasphaera*, *Escherichia-Shigella*, *Veillonella*, *Streptococcus*, *Fusobacterium*, and *Ruminococcus gnavus* are found to be overrepresented in the IR group. The relative abundances of *Faecalibacterium*, *Eubacterium rectale*, *Alistipes*, *Subdoligranulum*, *Bifidobacterium*, *Roseburia*, *Ruminococcaceae* and *Parasutterella* are higher in the healthy controls (Fig. 2 and S1 Fig. 2b) than in the IR group. A taxonomy-based bacterial comparison was conducted to define the differences between the healthy controls and the INR groups. At the phylum level, Bacteroidetes, Actinobacteria, Tenericutes and Lentisphaerae are more abundant in the healthy controls than those in the INR group, while Proteobacteria, Fusobacteria, Tenericutes, Saccharibacteria and unclassified k norank are more abundant in the INR group than those in the healthy controls (Fig. 2 and S1 Fig. 2c). At the genus level, the relative abundances of 83 genera (including 11 predominant genera) are different between the healthy controls and the INR groups. The relative proportions of *Faecalibacterium*, *Eubacterium rectale*, *Alistipes*, *Bifidobacterium*, *Blautia*, *Roseburia* and *Ruminococcaceae* are more abundant in the healthy controls than those in the INR group. *Parasutterella*, *Megasphaera*, *Fusobacterium*, and *Ruminococcus gnavus* are found to be overrepresented in the INR group (Fig. 2 and S1 Fig. 2d). Although there is no significant difference between the IR and the INR group at the phylum level (S1 Fig. 2e), the abundances of 12 genera (including 2 predominant genera) are different between the IR and INR groups. The abundances of the two predominant genera *Escherichia-Shigella* and *Blautia* are significantly higher in the IR than those in the INR group (Fig. 2 and S1 Fig. 2f).

In order to identify the key phylotypes responsible for the difference found in distinguishing fecal microbiota of different groups, linear discriminant analysis (LDA) effect size (LEfSe) was performed and a threshold of three on effect size was used. Taxonomic cladograms which represents the microbiota structure and predominant bacteria in the three groups is presented, and the biggest differences between the two communities are presented in S4 Fig.
Comparison of the T-cell activation in the IR and INR groups

As expected, nadir CD4+ T-cell, current CD4+ T-cell counts and CD4/CD8 ratio are lower in the INR group than those in the IR group (p<0.0001). The proportion of CD8+CD57+ T-cell in the INR group is significantly lower than those in the IR group (p<0.001). The proportion level of CD4+ and CD8+ T-cells immune activation (CD4/8+ T-cell by the expression of CD25+, HLA-DR+, and HLA-DR+/CD38+) is similar in the INR and IR groups (Table 1).

Comparison of the bacterial translocation markers and inflammation profiles

Lipopolysaccharide (LPS), which translocates from the gut to the blood stream, is commonly used as the major antigens to drive the chronic immune activation. The level of LPS is significantly higher in the INR group compared with other groups (p<0.0001). However, the soluble immune activation marker sCD14 shows no difference between the groups. Of the 13 markers studied, the level of IL-13 shows no difference among groups while the other twelve markers (IL-2, IL-4, IL-5, IL-6, IL-9, IL10, IL-17A, IL-17F, IL-21, IL-22, IFN-γ and TNF-α) appear to be significantly higher in the INR and IR groups when compared with the healthy controls, but there is no significant difference between the INR and IR groups (Table 1).

Association between fecal microbiota and immune activation

Spearman correlations of the relative abundances of bacteria genera and levels of T-cell activation, inflammation or translocation biomarkers are evaluated (Fig. 3). Interestingly, nadir CD4+ T-cell counts are positively correlated with the abundances of Ruminococcaceae and Alistipes, while current CD4+ T-cell counts are strongly positively correlated with the abundances of Ruminococcaceae and Subdoligranulum. The genus Fusobacterium is negatively correlated with nadir and current CD4+ T-cell. The CD4/CD8 ratio is positively correlated with the genus Faecalibacterium and Ruminococcaceae, but negatively correlates with Escherichia-Shigella. Moreover, the CD8+CD57+ T-cell counts is positively correlated with Escherichia-Shigella but negatively correlates with the genus Ruminococcaceae and Alistipes. The genus Roseburia and Blautia are negatively associated with nadir CD4+ T-cell and positively associated with CD8+CD57+ T-cell counts. Inflammation markers and LPS are positively correlated with the Ruminococcus and Fusobacterium but negatively correlates with the genus Faecalibacterium (Fig. 3).

Discussion

The objective of highly active antiretroviral therapy (HAART) is to achieve immune reconstitution and successful viral suppression in HIV-infected patients [2]. Even with complete viral suppression, the CD4+ T cell cannot be reversed completely and microbial translocation continues after peripheral CD4+ T cell restoration [20-23]. Gut microbiota has been reported to have critical impact on human biology and pathophysiology. The gut microbiota's function as a key factor in the process of immune homeostasis is accepted widely by the research community now [23]. Compositional and functional changes of the gut microbiota have indicated a new relationship between the gut bacterial community and immunity in HIV-
infected individuals with treatments [7, 24-26]. However, the way the microbiome contributes to immune response in HIV positive individuals is poorly understood. So, the objective of this study is to investigate the relationship between the fecal microbiome and immune activation in HIV-positive individuals with different immune responses to long-term ART in China.

The microbiome dysbiosis in HIV-infected individuals has been introduced in several studies [7, 25, 26]. However, early studies only adopted a small amount of IR and INR patients as subjects [8, 10] and did not taken immune response to HAART into consideration [27]. The previous studies showed that the relative abundance of *Fusobacterium* was independently associated with poorer CD4+ T-cell recovery[10], and the relative abundances of unclassified *Subdoligranulum sp.* and *C. comas* were positively correlated with CD8+HLA-DR+ T-cell counts and CD8+HLADR+/CD8+ percentage in the HIV-infected subjects[8]. The current study has adopted higher number of IR and INR patients and have expanded the range of observations when investigating the relationship between the gut microbiota and immune activation. This study found that the ecological indices of microbiota (including community diversity, richness and observed species numbers) were significantly lower in the IR and INR groups when compared with the healthy controls. Additionally, PCoA analysis showed remarkable differentiation of bacterial communities between the IR, INR and the healthy controls. The findings suggested that HIV-infected immunological responders and immunological non-responders could not recover completely from the gut microbiota dysbiosis.

The phylum Fusobacteria (mostly driven by its constituent genus *Fusobacterium*) was reported to be associated with intestinal inflammation [37, 38] and was abundant in HIV-infected individuals in some studies [29, 33, 39, 40]. Here, this study found increased abundance of *Fusobacterium* in the IR and INR groups. Furthermore, inflammation markers and translocation biomarkers (LPS) were positively correlated with *Fusobacterium*, while the nadir and current CD4+ T-cell counts were negatively correlated with *Fusobacterium* in this study. This was consistent with the previous published studies which reported that the relative abundance of *Fusobacterium* was independently associated with poorer CD4+ T-cell recovery and the enrichment of *Fusobacterium* was associated with decreased ability of immune recovery and persistent immune dysfunction following ART[10].

The phylum Bacteroidetes, which include the families Bacteroidaceae, Prevotellaceae, Porphyromonadaceae and Rikenellaceae, exhibited a more heterogeneous pattern of changes in the HIV-infected individuals [11, 12, 23, 28-34, 39-42]. The family Bacteroidaceae (mostly driven by the abundance of the genus *Bacteroides*) which was generally considered to be playing an anti-inflammatory role [43-46], was depleted in the IR and INR groups. The bile-tolerant family Rikenellaceae (mostly driven by the abundance of the genus *Alistipes*) which had protective properties against *C. difficile* infection [46, 47], was overall depleted in the IR and INR groups. Actinobacteria, which was reported to be similar in the proximal gut of HIV-infected patients and negative controls [32], were depleted in the IR and INR groups in this study. The *Alistipes* was negatively correlated with the CD8+CD57+ T-cell and positively correlated with the nadir CD4+ T-cell counts. Notably, the commonly used probiotics *Bifidobacterium* which belong
to the phylum of Actinobacteria was depleted in the IR and INR groups compared with the healthy controls [48].

Although the abundance of phylum Firmicutes was similar in all three groups, genus such as *Faecalibacterium* and *Ruminococcaceae* were depleted in the IR and INR groups compared with the healthy controls. *Ruminococcaceae* has been playing both protective and disruptive roles within the gut microbial community, such as the production of anti-inflammatory short-chain fatty acids (SCFA) [49] or the degradation of host mucus and potential proinflammatory in IBD[50]. In this study, *Faecalibacterium* and *Ruminococcaceae UCG-002*, which belong to the family of *Ruminococcaceae* were depleted in the IR and INR groups compared with the healthy controls. Interestingly, *Ruminococcaceae* was positively correlated with the current nadir CD4+ T-cell counts while negatively correlated with the CD8+CD57+ T-cell counts. In addition, inflammation markers and LPS were positively correlated with the abundance of genus *Ruminococcus*. *Faecalibacterium* has been reported as the anti-inflammatory commensal genus [29, 51]. In this study, the genus *Faecalibacterium* was positively correlated with CD4/CD8 ratio while negatively correlated with the inflammation markers and LPS.

The normal (gut microbiota) groups which commonly present in large amounts in the healthy controls bear more significance and interest us more compared to various pathogens. Both *Roseburia* and *Blautia* (which belong to the phylum Firmicutes, class Clostridia, family Lachnospiraceae) were members of the groups of commensals like which described above and have been described as the SCFA producers with beneficial effect on the intestinal barrier and an important energy source for epithelial cells [52]. In this study, *Blautia, and Roseburia* were more abundant in the healthy controls and the abundance of *Blautia* increased significantly in the IR group than the INR group. *Roseburia* and *Blautia* were negatively associated with the nadir CD4+ T-cell and positively associated with the CD8+CD57+ T-cell counts. These suggested that *Blautia* and *Roseburia* might be associated with the treatment outcome.

Altogether, these results indicate that immune activation in the HIV-infected patients was associated with the gut microbiota dysbiosis observed. Based upon these findings, this study speculate that the gut microbiota may be one of the factors contributing to different immune responses to HAART. *Fusobacterium, Alistipes, Ruminococcaceae, Faecalibacterium, Escherichia-Shigella, Roseburia* and *Blautia* maybe the major genus contributing to different immune responses and treatment outcome in immunodiscordant and immunoconcordant patients with long-term suppressive ART. However, we did not collect samples before the ART treatment, so future research on whether the gut microbiome composition influences treatment effect or not is still needed and this study cannot directly address the question if changes in the microbiota were causative or rather a result of systemic HIV-1-associated immune activation. This study acknowledges that the extensive dietary data and various living conditions of the subjects involved may lead to biases during the analysis. On the other hand, while correlation analysis was helpful in linking biological clues to the impact of dysbiosis in immune responses in the patients, a direct manipulation of the microbiome was needed to validate their cellular and biochemical actions in vitro or in vivo, and the exact mechanism of how HIV infection can lead to dysbiosis in the gut need to be studied in the future.
Conclusions

In summary, this study presents the research results regarding the gut microbiota dysbiosis in HIV-infected immunological non-responders and immunological responders, and concludes that the gut microbiota dysbiosis may be one of the factors contributing to different immune responses to HAART. *Fusobacterium, Alistipes, Ruminococcaceae, Faecalibacterium, Escherichia-Shigella, Roseburia and Blautia* may be the major genus contributing to different immune responses and treatment outcome in immunodiscordant and immunoconcordant patients with long-term suppressive ART.

Methods

Recruitment of subjects

The process of participants’ recruitment and sample collection is stated in Suppl. S5 Fig. 58 HIV-infected individuals in total, including 28 immunological responders (IR), 30 immunological non-responders (INR), and 36 healthy subjects (healthy controls) were recruited. IR and INR were defined as patients whose CD4+ T-cell counts/µl equal or is more than 500 or less than 200 after 2 years of receiving complete viral suppression therapy respectively. Subjects were recruited from the HIV clinic of the First Affiliated Hospital of Zhejiang University from November 2015 to October 2017. All HIV-positive participants were diagnosed by the Disease Control and Prevention Center of Zhejiang Province. All HIV-positive subjects were on two nucleoside reverse transcriptase inhibitors (NRTIs) + nonnucleoside reverse transcriptase inhibitors (NNRTIs) or the protease inhibitor-based therapy: Zidovudine/Tenofovir Disoproxil Fumarate (AZT/TDF) + Lamivudine(3TC) + Efavirenz (EFV) or Lopinavir/ritonavir (LPV/r). The healthy controls were all healthy HIV-negative volunteers and most of them belong to the staff of the institution. Age, gender, and body mass index (BMI) of the healthy controls are similar to those of the HIV-positive individuals (Table 1). Candidates with following conditions and traits are excluded from the subject selection: age over 60 years old; having opportunistic infection; having hepatitis B or C infection; having history of using antibiotics, immunosuppressive regimen, probiotics, prebiotics, or symbiotics in the previous 6 months; having used rectally administered medications within 48h before selection; BMI >30; having a history of inflammatory bowel disease (IBD); having active inflammation affecting the gastro intestines.

Ethics Statement

All participants provided written informed consents before participating in the study. This study conforms to the ethical norms of the 1975 Helsinki Declaration. The research protocol was approved by the Institutional Review Committee of the First Affiliated Hospital of Zhejiang University on October 7, 2015. All the data used for analysis were anonymized.

Fecal samples collection and DNA extraction

Fecal samples of the participants were collected in sterile container before their clinic visits and were stored in a −80°C environment before the DNA extraction. The DNA was extracted using a QIAamp DNA
stool mini kit (QIAGEN, Hilden, Germany) and glass-bead beat on Mini-bead beater (FastPrep; Thermo Electron Corporation, Boston, MA, USA), following the manufacturer’s instructions. The DNA’s quantification and purity were assessed by NanoDrop ND-1000 spectrophotometer (Thermo Electron Corporation). The integrity and sizes of the DNA were reviewed by 1.0% agarose gel electrophoresis. The DNA was stored at a −20 °C environment for further analysis.

**Polymerase chain reaction (PCR) and 16S rRNA gene sequencing**

PCR amplification of the bacterial 16S rRNA gene V3–V4 region was performed using universal primers (338F 5'- ACTCCTACGGGAGGCAGCAG-3', 806R 5'-GGACTACHVGGGTWTCTAAT-3'). The PCR reactions were conducted using the following program: 3 mins of denaturation at 95 °C, 27 cycles of 30s at 95 °C, 30s for annealing at 55 °C, and 45s for elongation at 72 °C, and a final extension at 72 °C for 10 mins. PCR reactions were performed in a triplicate 20 µl mixture containing 4 µl of 5 × FastPfu Buffer, 2 µl of 2.5 mM dNTPs, 0.8 µl of each primer (5 µM), 0.4 µl of FastPfu Polymerase and 10 ng of the template DNA. The resulted PCR products were extracted from a 2% agarose gel and then purified using the AxyPrep DNA Gel Extraction Kit (Axygen Biosciences, Union City, CA, USA) and quantified using QuantiFluor™-ST (Promega, USA) following the manufacturer’s protocol. Purified amplicons were pooled in equimolar and paired-end sequenced (2 × 300) on an Illumina MiSeq platform (Illumina, San Diego, USA) following the standard protocols by Majorbio Bio-Pharm Technology Co. Ltd. (Shanghai, China). The raw reads were deposit into the NCBI Sequence Read Archive (SRA) database and is accessible with the following link: 
https://www.ncbi.nlm.nih.gov/sra/PRJNA533202.

**Bioinformatics and statistics**

The raw fastq files were demultiplexed and quality-filtered using Trimmomatic, and then merged by FLASH. The original reads were trimmed with a minimum length of 50bp with an average quality score of 20. Two mismatches were allowed in primer sequences and reads containing ambiguous bases were removed. Ten homopolymers authorized in sequences were limited. OTUs were picked at a 97% similar threshold by UPARSE (http://drive5.com/uparse/) and chimera identification sequence was performed using UCHIME. Taxonomy-based analyses were performed by RDP Classifier algorithm (http://rdp.cme.msu.edu/) in combination with 16s rRNA Silva128 database with 70% cut-off confidence.

**Viral Load, Flow Cytometry and Immunophenotype**

Quantifications of CD4+ and CD8+ T-cells as well as HIV-1 RNA were carried out in HIV-infected individuals using flow cytometry and Cobas Amplicor (Roche Molecular Systems Inc., Branchburg, New Jersey, USA) as the clinical routine. The percentage of CD4+ and CD8+ T cells expressing markers of activation (CD25+, CD38+, HLADR+, or CD38+/HLA-DR+) and senescence (CD57+) were quantified by the BD FACS Canto II flow cytometer (BD Biosciences, California, USA) using fresh anticoagulated whole blood. Antibody such as CD3-FITC, CD4- PerCP/Cy5.5, CD8-Brilliant Violet 510™, CD38-Brilliant Violet 421,
CD25-PE, HLA-DR-APC/Fire™ 750, and CD57-allophycocyanin (APC) were purchased from Biolegend (San Diego, CA).

**Bacterial translocation and immune activation markers**

Sera samples of 27 IR, 30 INR, and seventeen healthy participants were collected for the measurement of the immune activation markers. These markers were quantified using LEGENDplex™ Human Th Cytokine Panel (Biolegend, San Diego, CA): IL-2, IL-4, IL-6, IL-9, IL10, IL-13, IL-17A, IL-17F, IL-21, IL-22, TNF-α and interferon (IFN)-γ, in line with the manufacturer's instructions. Human Lipopolysaccharides (LPS) ELISA Kit (CUSABIO; Wuhan, China) and Human soluble CD14 (sCD14) ELISA Kit (MultiSciences, Hangzhou, China) were used to test the plasma LPS and sCD14 following the standard protocols. Two replicates were performed for each assay.

**Statistics analysis**

OTUs that reached the 97% level of nucleotide similarity level were used for alpha diversity (Shannon, Simpson, and Sobs), richness (ACE and Chao1), Good's coverage, and rarefaction curve, and phylogenetic beta diversity measures analyses by mothur. PERMANOVA (permutational multivariate analysis of variance) were used to assess beta diversity based on the UniFrac distances. The number of permutations was 999 for PERMANOVA. The results were imported into Phyloseq for subsampling normalization, manipulation, and graph visualization by R (V.3.1.3, The R Project for Statistical Computing)[53]. Linear discriminant analysis (LDA) effect size (LEfSe) used the Kruskal-Wallis rank sum test to detect features with significant different abundances between the assigned taxa. LEfSe is available online in the Galaxy workflow framework[54]. Principal Coordinates analysis (PCoA) was conducted for weighted Unifrac data to visualize the microbial communities. The one-way ANOVA, non-parametric test, Wilcoxon rank sum test and Mann-Whitney U test which used for comparisons between groups were conducted in the R package and SPSS software (version 21, SPSS, Inc., Chicago, IL, USA). The average abundance values for each bacterium are depicted as mean ± SD. A significant alpha of 0.05 and LDA effect size threshold of 3 were used for all biomarkers. Correlations between the variables were calculated using the Spearman's rank-correlation analysis by R package; and associations with the Benjamini-Hochberg adjusted p-value lower than 0.01 were considered relevant.

**Abbreviations**

HIV: human immunodeficiency virus; ART: antiretroviral therapy; HAART: highly active antiretroviral therapy; INR: immunological non-responders; IR: immunological responders; BMI: body mass index; MSM: men who have sex with men; SCFA: short-chain fatty acids; LPS: Lipopolysaccharide; PCoA: Principal coordinate analysis; LDA: Linear discriminant analysis; LEfSe: linear discriminant analysis effect size; OTU: operational taxonomic unit; 16S rRNA: 16S ribosomal RNA; NRTIs: nucleoside reverse transcriptase inhibitors; NNRTIs nonnucleoside reverse transcriptase inhibitors; AZT: Zidovudine; TDF: Tenofovir Disoproxil Fumarate; 3TC: Lamivudine; EFV: Efavirenz; LPV/r: Lopinavir/ritonavir.
Declarations

Ethics approval and consent to participate

This study conforms to the ethical norms of the 1975 Helsinki Declaration. The research protocol was approved by the Institutional Review Committee of the First Affiliated Hospital of Zhejiang University on October 7, 2015. All data analyzed were anonymized. All participants provided a written informed consent before entering the study.

Consent to publication

Not applicable.

Availability of data and materials

The raw reads were deposited into the NCBI Sequence Read Archive (SRA) database and is accessible with the following link: https://www.ncbi.nlm.nih.gov/sra/PRJNA533202.

Competing interests

The authors declare that they have no conflict of interests.

Informed consent: Written consent was obtained from the patients.

Funding

This study is funded by the Natural Science Foundation of China (Young Scientist Fund, 81500491) and the National Science Foundation of China (Major Research Plan, 2018ZX10715-014). These funding agencies have no role in the design, data collection, analysis or interpretation of the research or in the writing of the manuscript.

Author Contributions

Y.X. participated in the designing of the study and performed the statistical analysis and wrote the paper. J.S. performed the statistical analysis and revised the paper. L. W., H.J., C.H. and J.Y. carried out the experiment. C.H. and Y.H. collected the biopsy samples. B.R. helped to review the manuscript. B.Z. participated in the designing and reviewing of the manuscript. All authors read through and approved the final manuscript.

Acknowledgments

This study gratefully acknowledges the patients who participated in the research.

References
1. Kelley CF, Kitchen CM, Hunt PW, Rodriguez B, Hecht FM, Kitahata M, Crane HM, Willig J, Mugavero M, Saag M et al: Incomplete peripheral CD4+ cell count restoration in HIV-infected patients receiving long-term antiretroviral treatment. Clin Infect Dis 2009, 48(6):787-794.

2. Cenderello G, De Maria A: Discordant responses to cART in HIV-1 patients in the era of high potency antiretroviral drugs: clinical evaluation, classification, management prospects. Expert Rev Anti Infect Ther 2016, 14(1):29-40.

3. Tsukamoto H, Clise-Dwyer K, Huston GE, Duso DK, Buck AL, Johnson LL, Haynes L, Swain SL: Age-associated increase in lifespan of naïve CD4 T cells contributes to T-cell homeostasis but facilitates development of functional defects. Proc Natl Acad Sci U S A 2009, 106(43):18333-18338.

4. Florence E, Lundgren J, Dreezen C, Fisher M, Kirk O, Blaxhult A, Panos G, Katlama C, Vella S, Phillips A et al: Factors associated with a reduced CD4 lymphocyte count response to HAART despite full viral suppression in the EuroSIDA study. HIV Med 2003, 4(3):255-262.

5. Kaufmann GR, Perrin L, Pantaleo G, Opravil M, Furrer H, Telenti A, Hirschel B, Ledergerber B, Vernazza P, Bernasconi E et al: CD4 T-lymphocyte recovery in individuals with advanced HIV-1 infection receiving potent antiretroviral therapy for 4 years: the Swiss HIV Cohort Study. Arch Intern Med 2003, 163(18):2187-2195.

6. Gazzola L, Tincati C, Bellistri GM, Monforte A, Marchetti G: The absence of CD4+ T cell count recovery despite receipt of virologically suppressive highly active antiretroviral therapy: clinical risk, immunological gaps, and therapeutic options. Clin Infect Dis 2009, 48(3):328-337.

7. Gootenberg DB, Paer JM, Luevano JM, Kwon DS: HIV-associated changes in the enteric microbial community: potential role in loss of homeostasis and development of systemic inflammation. Curr Opin Infect Dis 2017, 30(1):31-43.

8. Lu W, Feng Y, Jing F, Han Y, Lyu N, Liu F, Li J, Song X, Xie J, Qiu Z et al: Association Between Gut Microbiota and CD4 Recovery in HIV-1 Infected Patients. Front Microbiol 2018, 9:1451.

9. Ji Y, Zhang F, Zhang R, Shen Y, Liu L, Wang J, Yang J, Tang Q, Xun J, Qi T et al: Changes in intestinal microbiota in HIV-1-infected subjects following cART initiation: influence of CD4+ T cell count. Emerg Microbes Infect 2018, 7(1):113.

10. Lee SC, Chua LL, Yap SH, Khang TF, Leng CY, Raja Azwa RI, Lewin SR, Kamarulzaman A, WooYL, Lim YAL et al: Enrichment of gut-derived Fusobacterium is associated with suboptimal immune recovery in HIV-infected individuals. Sci Rep 2018, 8(1):14277.

11. Sun Y, Ma Y, Lin P, Tang YW, Yang L, Shen Y, Zhang R, Liu L, Cheng J, Shao J et al: Fecal bacterial microbiome diversity in chronic HIV-infected patients in China. Emerg Microbes Infect 2016, 5:e31.

12. Ling Z, Jin C, Xie T, Cheng Y, Li L, Wu N: Alterations in the Fecal Microbiota of Patients with HIV-1 Infection: An Observational Study in A Chinese Population. Sci Rep 2016, 6:30673.

13. Deeks SG, Tracy R, Douek DC: Systemic effects of inflammation on health during chronic HIV infection. Immunity 2013, 39(4):633-645.

14. West CE, Renz H, Jenmalm MC, Kozyrskyj AL, Allen KJ, Vuillermin P, Prescott SL, in FMIG: The gut microbiota and inflammatory noncommunicable diseases: associations and potentials for gut
microbiota therapies. *J Allergy Clin Immunol* 2015, **135**(1):3-13; quiz 14.

15. Klatt NR, Chomont N, Douek DC, Deeks SG: Immune activation and HIV persistence: implications for curative approaches to HIV infection. *Immunol Rev* 2013, **254**(1):326-342.

16. Klatt NR, Funderburg NT, Brenchley JM: Microbial translocation, immune activation, and HIV disease. *Trends Microbiol* 2013, **21**(1):6-13.

17. Lederman MM, Funderburg NT, Sekaly RP, Klatt NR, Hunt PW: Residual immune dysregulation syndrome in treated HIV infection. *Adv Immunol* 2013, **119**:51-83.

18. Siedner MJ: START or SMART? Timing of Antiretroviral Therapy Initiation and Cardiovascular Risk for People With Human Immunodeficiency Virus Infection. *Open Forum Infect Dis* 2016, **3**(1):ofw032.

19. Havlir DV, Currier JS: CROI 2015: Complications of HIV Infection and Antiretroviral Therapy. *Top Antivir Med* 2015, **23**(1):56-65.

20. Jiang W, Lederman MM, Hunt P, Sieg SF, Haley K, Rodriguez B, Landay A, Martin J, Sinclair E, Asher Al et al: Plasma levels of bacterial DNA correlate with immune activation and the magnitude of immune restoration in persons with antiretroviral-treated HIV infection. *J Infect Dis* 2009, **199**(8):1177-1185.

21. Mavigner M, Cazabat M, Dubois M, L'Faqihi FE, Requena M, Pasquier C, Klopp P, Amar J, Alric L, Barange K et al: Altered CD4+ T cell homing to the gut impairs mucosal immune reconstitution in treated HIV-infected individuals. *J Clin Invest* 2012, **122**(1):62-69.

22. Neuhaus J, Jacobs DR, Jr., Baker JV, Calmy A, Duprez D, La Rosa A, Kuller LH, Pett SL, Ristola M, Ross MJ et al: Markers of inflammation, coagulation, and renal function are elevated in adults with HIV infection. *J Infect Dis* 2010, **201**(12):1788-1795.

23. Vazquez-Castellanos JF, Serrano-Villar S, Latorre A, Artacho A, Ferrus ML, Madrid N, Vallejo A, Sainz T, Martinez-Botas J, Ferrando-Martinez S et al: Altered metabolism of gut microbiota contributes to chronic immune activation in HIV-infected individuals. *Mucosal Immunol* 2015, **8**(4):760-772.

24. Cho I, Blaser MJ: The human microbiome: at the interface of health and disease. *Nat Rev Genet* 2012, **13**(4):260-270.

25. Lujan JA, Rugeles MT, Taborda NA: Contribution of the Microbiota to Intestinal Homeostasis and its Role in the Pathogenesis of HIV-1 Infection. *Curr HIV Res* 2019, **17**(1):13-25.

26. Vujkovic-Cvijin I, Somsouk M: HIV and the Gut Microbiota: Composition, Consequences, and Avenues for Amelioration. *Curr HIV/AIDS Rep* 2019, **16**(3):204-213.

27. Tincati C, Merlini E, Braidotti P, Ancona G, Savi F, Tosi D, Borghi E, Callegari ML, Mangiavillano B, Barassi A et al: Impaired gut junctional complexes feature late-treated individuals with suboptimal CD4+ T-cell recovery upon virologically suppressive combination antiretroviral therapy. *AIDS* 2016, **30**(7):991-1003.

28. Lozupone CA, Rhodes ME, Neff CP, Fontenot AP, Campbell TB, Palmer BE: HIV-induced alteration in gut microbiota: driving factors, consequences, and effects of antiretroviral therapy. *Gut Microbes* 2014, **5**(4):562-570.
29. Mutlu EA, Keshavarzian A, Losurdo J, Swanson G, Siewe B, Forsyth C, French A, Demarais P, Sun Y, Koenig L et al: A compositional look at the human gastrointestinal microbiome and immune activation parameters in HIV infected subjects. PLoS Pathog 2014, 10(2):e1003829.

30. Vujkovic-Cvijin I, Dunham RM, Iwai S, Maher MC, Albright RG, Broadhurst MJ, Hernandez RD, Lederman MM, Huang Y, Somsouk M et al: Dysbiosis of the gut microbiota is associated with HIV disease progression and tryptophan catabolism. Sci Transl Med 2013, 5(193):193ra191.

31. Dillon SM, Lee EJ, Kotter CV, Austin GL, Dong Z, Hecht DK, Gianella S, Siewe B, Smith DM, Landay AL et al: An altered intestinal mucosal microbiome in HIV-1 infection is associated with mucosal and systemic immune activation and endotoxemia. Mucosal Immunol 2014, 7(4):983-994.

32. Yang L, Poles MA, Fisch GS, Ma Y, Nossa C, Phelan JA, Pei Z: HIV-induced immunosuppression is associated with colonization of the proximal gut by environmental bacteria. AIDS 2016, 30(1):19-29.

33. Dubourg G, Lagier JC, Hue S, Sureauad M, Bachar D, Robert C, Michelle C, Ravaux I, Mokhtari S, Million M et al: Gut microbiota associated with HIV infection is significantly enriched in bacteria tolerant to oxygen. BMJ Open Gastroenterol 2016, 3(1):e000080.

34. Dinh DM, Volpe GE, Duffalo C, Bhalchandra S, Tai AK, Kane AV, Wanke CA, Ward HD: Intestinal microbiota, microbial translocation, and systemic inflammation in chronic HIV infection. J Infect Dis 2015, 211(1):19-27.

35. Appay V, Sauce D: Immune activation and inflammation in HIV-1 infection: causes and consequences. J Pathol 2008, 214(2):231-241.

36. Ivanov, II, Frutos Rde L, Manel N, Yoshinaga K, Rifkin DB, Sartor RB, Finlay BB, Littman DR: Specific microbiota direct the differentiation of IL-17-producing T-helper cells in the mucosa of the small intestine. Cell Host Microbe 2008, 4(4):337-349.

37. Nicholson JK, Holmes E, Kinross J, Burcelin R, Gibson G, Jia W, Pettersson S: Host-gut microbiota metabolic interactions. Science 2012, 336(6086):1262-1267.

38. Kostic AD, Chun E, Robertson L, Glickman JN, Gallini CA, Michaud M, Clancy TE, Chung DC, Lochhead P, Hold GL et al: Fusobacterium nucleatum potentiates intestinal tumorigenesis and modulates the tumor-immune microenvironment. Cell Host Microbe 2013, 14(2):207-215.

39. McHardy IH, Li X, Tong M, Ruegger P, Jacobs J, Borneman J, Anton P, Braun J: HIV Infection is associated with compositional and functional shifts in the rectal mucosal microbiota. Microbiome 2013, 1(1):26.

40. Yu G, Fadrosh D, Ma B, Ravel J, Goedert JJ: Anal microbiota profiles in HIV-positive and HIV-negative MSM. AIDS 2014, 28(5):753-760.

41. Nowak P, Troseid M, Avershina E, Barqasho B, Neogi U, Holm K, Hov JR, Noyan K, Vesterbacka J, Svard J et al: Gut microbiota diversity predicts immune status in HIV-1 infection. AIDS 2015, 29(18):2409-2418.

42. Monaco CL, Gootenberg DB, Zhao G, Handley SA, Ghebremichael MS, Lim ES, Lankowski A, Baldridge MT, Wilen CB, Flagg M et al: Altered Virome and Bacterial Microbiome in Human
Immunodeficiency Virus-Associated Acquired Immunodeficiency Syndrome. *Cell Host Microbe* 2016, 19(3):311-322.

43. Troy EB, Kasper DL: Beneficial effects of *Bacteroides fragilis* polysaccharides on the immune system. *Front Biosci (Landmark Ed)* 2010, 15:25-34.

44. Round JL, Mazmanian SK: Inducible Foxp3+ regulatory T-cell development by a commensal bacterium of the intestinal microbiota. *Proc Natl Acad Sci U S A* 2010, 107(27):12204-12209.

45. Vatanen T, Kostic AD, d’Hennezel E, Siljander H, Franzosa EA, Yassour M, Kolde R, Vlamakis H, Arthur TD, Hamalainen AM et al: Variation in Microbiome LPS Immunogenicity Contributes to Autoimmunity in Humans. *Cell* 2016, 165(6):1551.

46. David LA, Maurice CF, Carmody RN, Gootenberg DB, Button JE, Wolfe BE, Ling AV, Devlin AS, Varma Y, Fischbach MA et al: Diet rapidly and reproducibly alters the human gut microbiome. *Nature* 2014, 505(7484):559-563.

47. Khanna S, Montassier E, Schmidt B, Patel R, Knights D, Pardi DS, Kashyap P: Gut microbiome predictors of treatment response and recurrence in primary *Clostridium difficile* infection. *Aliment Pharmacol Ther* 2016, 44(7):715-727.

48. Veiga P, Gallini CA, Beal C, Michaud M, Delaney ML, DuBois A, Khlebnikov A, van Hylckama Vlieg JE, Punit S, Glickman JN et al: *Bifidobacterium animalis* subsp. *lactis* fermented milk product reduces inflammation by altering a niche for colitogenic microbes. *Proc Natl Acad Sci U S A* 2010, 107(42):18132-18137.

49. Flint HJ, Bayer EA, Rincon MT, Lamed R, White BA: Polysaccharide utilization by gut bacteria: potential for new insights from genomic analysis. *Nat Rev Microbiol* 2008, 6(2):121-131.

50. Png CW, Linden SK, Gilshenan KS, Zoetendal EG, McSweeney CS, Sly LI, McGuckin MA, Florin TH: Mucolytic bacteria with increased prevalence in IBD mucosa augment in vitro utilization of mucin by other bacteria. *Am J Gastroenterol* 2010, 105(11):2420-2428.

51. Shaw KA, Bertha M, Hofmekler T, Chopra P, Vatanen T, Srivatsa A, Prince J, Kumar A, Sauer C, Zwick ME et al: Dysbiosis, inflammation, and response to treatment: a longitudinal study of pediatric subjects with newly diagnosed inflammatory bowel disease. *Genome Med* 2016, 8(1):75.

52. Schnorr SL, Candela M, Rampelli S, Centanni M, Consolandi C, Basaglia G, Turroni S, Biagi E, Peano C, Severgnini M et al: Gut microbiome of the Hadza hunter-gatherers. *Nat Commun* 2014, 5:3654.

53. McMurdie PJ, Holmes S: *phylseq*: an R package for reproducible interactive analysis and graphics of microbiome census data. *PLoS One* 2013, 8(4):e61217.

54. Goecks J, Nekrutienko A, Taylor J, Galaxy T: Galaxy: a comprehensive approach for supporting accessible, reproducible, and transparent computational research in the life sciences. *Genome Biol* 2010, 11(8):R86.

**Tables**

**Table 1. Clinical characteristics data summary**
Table 2. Cellular immune activation markers sequencing data summary

|                                      | Health Control | HIV ART (+) | Immune Responders (IR) | Immune Non-responders (INR) | P-value |
|--------------------------------------|----------------|-------------|------------------------|-----------------------------|---------|
| Number of subjects                   | 36             | 28          | 30                     |                             |         |
| Gender male/female                   | 33/3           | 25/3        | 29/1                   |                             |         |
| Age (mean± SD)                       | 33.11± 3.95    | 36.64±10.2  | 36.6±7.19              | NS                          |         |
| BMI (mean± SD)                       | 21.42±3.27     | 21.06±2.37  | 20.67±2.74             | NS                          |         |
| Smoking                              | 1              | 0           | 1                      | NS                          |         |
| Transmission, no.                    | NA             | 6           | 6                      | NS                          |         |
| Heterosexual                         | NA             | 16          | 15                     | NS                          |         |
| Homosexual transmission              | NA             | 6           | 8                      | NS                          |         |
| Data Missing                         | NA             | 37.25±13.61 | 34.00±10.24            | NS                          |         |
| Ongoing cART regimen, no. patients (%) | NA             | 25          | 27                     | NS                          |         |
| NNRTI based                          | NA             | 3           | 3                      | NS                          |         |
| PI based                             | NA             | 3           | 3                      | NS                          |         |

NA (not available), NS (no significant) indicates p-value > 0.05, *compared between the IR and the INR group. NNRTI: Non-nucleoside reverse transcriptase inhibitors; PI: Protease inhibitor.
| Cell markers                          | Health Control | Immune Responders (IR) | Immune Non-responders (INR) | P-value |
|--------------------------------------|----------------|------------------------|----------------------------|---------|
| Nadir CD4+ T cells (mean± SD)        | NA             | 309.89± 128.81         | 95.23± 108.92              | <0.0001 |
| Current CD4+ T cells (mean± SD)      | NA             | 608.30± 158.25         | 230.5± 87.50               | <0.0001 |
| Current CD4+/CD8+ T-cell ratio       | NA             | 0.8±0.36               | 0.35±0.20                  | <0.0001 |
| HIV RNA                              | NA             | ND                     | ND                         |         |
| CD4+HLADR+CD38+                     | NA             | 7.72±4.30              | 10.30±10.45                | NS      |
| CD4+CD25+                            | NA             | 1.26±0.99              | 1.09±1.04                  | NS      |
| CD4+CD57+                            | NA             | 2.57±1.92              | 2.43±3.30                  | NS      |
| CD8+HLADR+CD38+                     | NA             | 20.68±11.35            | 23±12.39                   | NS      |
| CD8+CD57+                            | NA             | 14.36±7.11             | 23.98±12.30                | 0.001   |
| Cytokines                            |                |                        |                            |         |
| L-2 (pg/mL, mean± SD)                | 9.47±6.79      | 120.96±113.96          | 153.81±118.79              | <0.0001 |
| L-4 (pg/mL, mean± SD)                | 13.49±31.01    | 34.52±43.30            | 32.51±31.17                | 0.009   |
| L-6 (pg/mL, mean± SD)                | 8.39±12.57     | 126.90±95.33           | 130.82±60.62               | <0.0001 |
| L-9 (pg/mL, mean± SD)                | 3.68±6.20      | 94.00±78.07            | 96.57±48.71                | <0.0001 |
| L10 (pg/mL, mean± SD)                |                |                        |                            |         |
| L-13 (pg/mL, mean± D)                | 2.48±2.35      | 44.69±37.66            | 51.32±31.65                | <0.0001 |
| L-17A (pg/mL, mean± D)               | 85.45±65.02    | 96.76±71.54            | 82.94±62.96                | NS      |
| L-17F (pg/mL, mean± D)               | 26.22±52.89    | 133.41±161.61          | 94.80±83.84                | <0.0001 |
| L-21 (pg/mL, mean± D)                | 5.45±5.68      | 19.15±19.48            | 20.59±20.34                | <0.0001 |
| L-22 (pg/mL, mean± D)                | 41.33±48.87    | 104.43±88.11           | 93.84±56.89                | 0.002   |
| FN-γ (pg/mL, mean± D)                | 153.98±97.15   | 291.60±176.36          | 293.10±125.37              | 0.001   |
| TNF-α (pg/mL, mean± D)               | 12.55±29.52    | 81.57±84.50            | 69.36±83.42                | <0.0001 |
| LPS (pg/mL, mean± D)                 | 8.39±15.57     | 38.86±44.19            | 32.22±26.47                | <0.0001 |
| CD14 (pg/mL, mean± D)                | 1583.60±292.80 | 2480.42±999.88        | 2142.65±496.53             | <0.0001 |
| Pyrosequencing data                  |                |                        |                            |         |
| Sobs index#                          | 194.11±47.45   | 116.89±39.71           | 118.11±46.96               | <0.0001 |
| Shannon index#                       | 3.14±0.53      | 2.47±0.54              | 2.44±0.56                  | <0.0001 |
| Simpson index#                       | 0.12±0.09      | 0.19±0.11              | 0.19±0.13                  | <0.0001 |
| CE#                                  | 223.97±53.59   | 147.26±39.98           | 148.41±49.99               | <0.0001 |
| shao 1 index#                        | 224.29±54.76   | 144.52±45.25           | 145.37±51.01               | <0.0001 |
| Good’s coverage (%) #                | 99.82±0.04     | 99.87±0.04             | 99.87±0.04                 | <0.0001 |

# Indicates that the alpha diversity was calculated after the reads number of each sample were equalized.
NA (not available), ND (not detected), NS (no significant) indicates p-value > 0.05, *compared between the IR and the INR group.